Overview

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

Status:
Suspended
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With mCNV.
Phase:
Phase 1
Details
Lead Sponsor:
AnewPharma
Treatments:
Vorolanib